en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
5/2020
vol. 58
 
Share:
Share:
more
 
 
abstract:
Review paper

Mesenchymal stem cells in systemic sclerosis therapy

Daniel Witold Dudek
1
,
Ewa Walczuk
2
,
Anna Wajda
2
,
Agnieszka Paradowska-Gorycka
2

1.
Biostructure Center of the Medical University of Warsaw, Poland
2.
Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Reumatologia 2020; 58, 5: 324–330
Online publish date: 2020/10/18
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
Systemic sclerosis (SSc) is a rare autoimmune disorder with a high mortality rate. There are still many unknowns concerning the pathophysiology of this disease, due to its clinical heterogeneity. Since there is still no curative treatment, researchers focus on finding novel methods to help the patients. One of the valid options is cellular therapy, and mesenchymal stem cells (MSCs)-based therapy yields great expectations. These cells possess especially valuable attributes regarding key points of SSc. Nevertheless, the effectiveness and safety of this therapy must undergo a rigorous process of veri­fication.

In preclinical trials, animal models proved to be a valuable source of scientific knowledge regarding SSc. Because of that, it has been possible to test autologous or allogeneic MSCs from various sources in many clinical trials. A lot of aspects still have to be determined to assess their potential in the management of SSc, probably in association with other therapies.
keywords:

systemic sclerosis, mesenchymal stem cells, cell therapy





Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.